Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A new study finds that PSMA PET/CT-guided targeted biopsy can detect clinically significant prostate cancer in 37% of men, compared to 21% with systematic biopsy alone. Combining the two approaches increases the detection rate to 41%.
Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
A multidisciplinary approach is crucial for treating recurrent prostate cancer, combining advanced imaging, radiation, and systemic therapies to address microscopic disease. The case report follows Larry Hardesty, who underwent several clinical trials, including PSMA-targeted radioligand therapy, leading to undetectable PSA levels and ...
Researchers identified circLPAR3 as a key mediator of docetaxel resistance in prostate cancer, promoting tumor growth under chemotherapy by suppressing ferroptosis. The study highlights circLPAR3 as a promising biomarker for treatment response and suggests targeting its regulatory network could help overcome chemotherapy resistance.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A large Medicare analysis found that depression is associated with higher cancer mortality, while psychotherapy soon after diagnosis reduces cancer risk. Patients with depression had a 21% lower risk of cancer-specific mortality after receiving psychotherapy within four weeks of their diagnosis.
A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...
The analysis found that adding short-term androgen deprivation therapy (STADT) to radiation provided a greater benefit for patients with Luminal B tumors compared to those with non-LumB tumors. This suggests that tumor biology can help determine who may benefit from hormone therapy.
A new study found that a shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer. However, it was associated with a higher rate of grade 3 urinary adverse events, particularly cystitis and hematuria.
UCLA researchers present new radiotherapy research for prostate cancer, head and neck cancers, and personalized radiation therapy. A genetic test identifies men with prostate cancer at higher risk of urinary side effects after SBRT, suggesting personalized radiation treatment.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
A national study of 20,000 men with prostate cancer found that surgery led to higher rates of urinary incontinence and erectile dysfunction, while radiation was associated with urinary complications and higher all-cause mortality. Researchers emphasized that both treatments have long-term consequences and that risks and benefits should...
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
A study by the Medical University of Vienna shows that PSMA-PET/CT can detect 91% of clinically significant prostate cancers before biopsies, potentially preventing unnecessary procedures. The test's high detection rate and predictive value make it a promising diagnostic tool for suspected prostate cancer.
An international collaboration co-led by the CNIO has identified eight faulty DNA processes driving most prostate cancers, which differ between patients and influence tumor spread. The study offers potential for reliable prognostic markers and personalized treatment, but further validation is needed.
A new study has mapped eight genetic 'fingerprints' that may explain why some men develop aggressive prostate cancer, while others do not. The researchers found that errors during DNA replication play a crucial role in the development of prostate cancer.
A new study found that men with nonmetastatic prostate cancer who replaced saturated and animal fats with unsaturated and plant-based fats had a lower risk of death. Replacing about 10% of daily calories from animal fat with plant-based fat was associated with a 16% lower rate of death.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
A recent survey found that only 20% of men are aware of the potential prostate cancer risk associated with dairy consumption. The survey also showed that 66% of men plan to avoid dairy products after learning about the risk. A meta-analysis of 32 studies supports the link between high dairy intake and increased prostate cancer risk.
The NRG-GU005 trial shows that SBRT improves bowel health related quality of life in localized intermediate risk prostate cancer patients, with no significant impact on urinary HRQOL. SBRT is also associated with lower incontinence related quality of life and improved maintenance of erectile dysfunction compared to hypofractionated IMRT.
Prostate cancer cells rewire amino acid metabolism to override normal brakes on cholesterol production, fueling hormone therapy resistance. Restricting isoleucine and valine in the diet may slow tumor growth and improve treatment response, while boosting propionyl-CoA levels promotes tumor growth.
A national study found that about half of prostate cancer patients receiving focal therapy fell outside the recommended patient groups, highlighting the need for evidence-based treatment decisions. The study emphasizes the importance of understanding which patients are most likely to benefit from promising new treatments.
A randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer found that stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT for disease-free survival at 3 years. However, SBRT showed better bowel-related quality of life compared to IMRT.
Active surveillance for favorable-risk prostate cancer increased significantly in the Veterans Affairs healthcare system, with high rates among low-risk and intermediate-risk patients. This trend suggests that many veterans are avoiding unnecessary treatment, but disparities in care persist.
This retrospective study examines patterns and trends of focal therapy for nonmetastatic prostate cancer in US cancer centers. Focal therapy procedures remained uncommon, occurring mostly in low-, high-, or very-high-risk disease settings.
A retrospective cohort study of 16,924 men found metabolic syndrome and related abnormalities during the first year of treatment. Hypertension was the most common metabolic outcome among patients receiving concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor.
A new study found that the majority of veterans with low-risk prostate cancer pursued active surveillance in 2024, up from 27% in 2005. The study followed over 73,000 veterans and showed similar survival outcomes for surveillance compared to treatment.
A new study from Florida Atlantic University finds that men who consume high amounts of ultra-processed foods have increased risks of prostate cancer. Men with the highest UPF intake had a possible 34% higher risk, although the finding did not reach statistical significance.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A new study uses spatial transcriptomics to map the molecular evolution of prostate cancer and identifies key genes associated with disease progression. The research reveals that genetic malignancy in specific glandular epithelial regions tightly aligns with increasing clinical Gleason scores.
A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is associated with improved patient survival, and this cutoff may be the best metric for determining treatment success, according to investigators analyzing Veterans Health Administration data.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
A new study uses mathematical biomarkers to accurately predict prostate cancer patient outcomes and survival, outperforming traditional PSA monitoring. These metrics can inform personalized treatment protocols, enabling more effective adaptive therapy.
A phase 3 clinical trial led by Weill Cornell Medicine shows that adding a targeted radionuclide therapy drug to backbone therapy reduces disease progression in patients with PSMA-positive metastatic prostate cancer. The treatment may delay symptom progression and improve patient outcomes.
A team of researchers at UMass Amherst has developed an AI model, DiffuDose, that generates a patient's radiation dose map with gold-standard accuracy in under 23 seconds. This technology has the potential to unlock the full potential of radiopharmaceutical therapy for prostate cancer treatment.
Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...
A Rice University research team created prostate cancer cells that can survive high-force moments in the body, a process known as mechanoresistance. The study found that a gene called CALB2 plays a key role in this ability, with increased expression linked to metastatic cancer.
Researchers used advanced 3D genome mapping technology to study prostate cancer cells and discovered a new feature of gene control networks that could help fight cancer. The study found that enhancers work cooperatively in 3D networks, with some acting as central hubs that control many genes.
A recent cohort study found similar rates of secondary treatment receipt among men with localized prostate cancer by race, but observed mortality disparities persisted. These findings raise concerns about healthcare inequities and the need for targeted interventions to address racial disparities in cancer care.
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer most likely to benefit from <sup> 223 </sup> Ra radiopharmaceutical therapy and monitor their progress. The test showed associations between ctDNA profiles and clinical outcomes, including biomarker response and overall survival.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
The study creates a radiohybrid approach that labels a single molecule with two different diagnostic radionuclides, enabling long-term visualization of therapeutic agent distribution. This allows for personalized cancer medicine by calculating optimal radiation doses for individual patients.
A new study identifies a rare genetic mutation in the CDK12 gene as a cause of aggressive prostate cancer at a young age. Genetic testing for this mutation could help identify families at risk and support early cancer detection, potentially saving lives.
A second PSMA PET scan changed treatment plans for nearly half of patients whose first scan was negative, detecting evidence of disease in 56% of cases. The study found that repeat imaging was most likely to detect disease in patients with higher PSA levels and a PSA doubling time of less than twelve months.
Researchers at the University of Texas MD Anderson Cancer Center have identified genetic factors that determine whether prostate cancers are susceptible to ferroptosis. SPOP mutations and CHD1 deletions could serve as biomarkers to help identify patients who may benefit from emerging ferroptosis-based therapies.
Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A new blood test, Stockholm3, detected significantly more aggressive prostate cancers than the PSA test without increasing unnecessary follow-ups. The study shows that Stockholm3 identifies 90% of aggressive cancer cases, compared to 74% for PSA.
A new study found that conversations about prostate cancer screening are uncommon in primary care visits but lead to higher screening rates when they do occur. The study suggests a gap between national guidelines and clinical practice, highlighting the importance of shared decision-making for individualized care.
A hospital-based study in India found that higher coffee consumption and meat intake were associated with lower odds of prostate cancer. The researchers identified potential biological mechanisms behind these findings, but note that the relationship between diet and prostate cancer is complex and warrants further investigation.
Prostate cancer cells use the PIM1 protein to survive treatment by activating autophagy, a cellular recycling process. Researchers have discovered a potential strategy to overcome this resistance by removing the PIM1 protein entirely using a proteolysis-targeting chimera.
A new division at the James Buchanan Brady Urological Institute will support research, education, and care for urological conditions. The gift will accelerate advancements in surgical training, imaging, and technology to improve patient outcomes.
Researchers at UT MD Anderson Cancer Center have made significant advances in understanding cancer biology, developing AI-powered atlas of tertiary lymphoid structures as prognostic biomarkers, and uncovering drivers of resistance to KRAS inhibitors. Additionally, they have discovered a molecular pathway that drives stressed cells to b...
A recent study analyzing 670,000 patients found a higher frequency of advanced disease among non-white men and differences in access to modern therapies. The study also revealed significant racial inequalities in treatment costs, with white patients receiving 16.2% more funding.
A phase 3 clinical trial found that apalutamide plus hormone therapy before and after surgery reduced the risk of metastasis or death by 20% compared to hormone therapy alone. Patients treated with this regimen had a higher pathologic response rate and experienced delayed subsequent therapy.
Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.
A new poll by Physicians Committee for Responsible Medicine finds that most men consider a carnivore diet to be 'masculine' and would change their diet if it put their health at risk. The survey also found that consuming meat is linked to an increased risk of heart disease, erectile dysfunction, and reduced fertility.
Researchers discovered that androgen receptor signaling acts as a transcriptional repressor of liver receptor homolog-1 (LRH-1) in prostate cancer. This finding reveals a previously unknown mechanism of gene regulation and highlights the potential for targeting this axis to manage advanced prostate cancer.